5 drugs recalled during May, FDA reports

Pexels.com

Five drugs were recalled in May to protect patients from possible harmful defects associated with the products, the U.S. Food and Drug Administration reported.

Such recalls are voluntary actions carried out by drug makers to remove potentially defective medicines from the market, the FDA said. They may be initiated either by the manufacturer or the FDA.

---

Drug Recalls for May

Date	Brand Name	Product Description	Reason/ Problem	Company
May 29	Pecgen DMX,	PECGEN DMX, 16 oz., liquid cough syrup	Mislabeling	NOVIS PR LLC
May 28	Heritage	Amikacin Sulfate Injection, USP, 1g/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP, 10mg/2mL (5mg/mL)	Potential Lack of Sterility	Heritage Pharmaceuticals Inc.
May 11	Promacta	Promacta 12.5 mg oral suspension	Potential Foreign Material	Novartis
May 3	Heritage	Losartan Potassium Tablets USP	Defect	Vivimed
May 1	Par Pharmaceutical	Mycophenolate Mofetil for injection	Potential Foreign Material	Par Pharmaceutical Inc.

Source: U.S. Food and Drug Administration